Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
49.72 BRL | -2.15% | -3.34% | -1.35% |
28/05 | Sector Update: Health Care Stocks Fall Late Afternoon | MT |
28/05 | Sector Update: Health Care Stocks Retreat Tuesday Afternoon | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's enterprise value to sales, at 3.85 times its current sales, is high.
- The company appears highly valued given the size of its balance sheet.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.35% | 35TCr | - | ||
+38.59% | 73TCr | C+ | ||
+15.66% | 32TCr | B- | ||
+0.24% | 27TCr | C+ | ||
+13.74% | 24TCr | B+ | ||
+7.06% | 20TCr | B- | ||
-6.30% | 20TCr | A+ | ||
+4.23% | 16TCr | C+ | ||
-1.70% | 16TCr | C+ | ||
-1.78% | 12TCr | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- JNJ Stock
- JNJB34 Stock
- Ratings Johnson & Johnson